Skip to main content
. Author manuscript; available in PMC: 2014 Oct 28.
Published in final edited form as: Cancer Discov. 2011 Jun 1;1(1):44–53. doi: 10.1158/2159-8274.CD-10-0010

Table 2.

Efficacy Result by Marker Groups

Disease Control by Treatment and Marker Groups Number of DC / Total Number of Patients (%)
Marker Group Treatment Total
Erlotinib Vandetanib Erlotinib + Bexarotene Sorafenib
EGFR 6/17 (35%) 11/27 (41%)* 11/20 (55%)* 9/23 (39%) 37/87 (43%)
KRAS/BRAF 1/7 (14%) 0/3 (0%) 1/3 (33%) 11/14 (79%)* 13/27 (48%)
VEGF/VEGFR-2 10/25 (40%)* 6/16 (38%) 0/3 (0%) 25/39 (64%)* 41/83 (49%)
RXR/Cyclin D1 0/1 (0%) 0/0 ( NA ) 1/1 (100%)* 1/4 (25%) 2/6 (33%)
None 3/8 (38%) 0/6 (0%) 5/9 (56%)* 11/18 (61%)* 19/41 (46%)
Total 20/58 (34%) 17/52 (33%) 18/36 (50%) 57/98 (58%) 112/244 (46%)
*

Cells with an asterisk show the effective treatments within specific marker groups defined as Probability (Disease control rate > 30% | data) is 80% or greater. Only one patient in the RXR/CycD1 marker group received erlotinib+bexarotene.